Patent details

LUC50012 Product Name: garadacimab

Basic Information

Publication number:
LUC50012
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP127359164
Legal Status:
Pending & Published
Application number:
LUC50012
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/24/1885
Marketing Authorization Type:
Marketing Authorization Date:
12/02/2025
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
18/06/2025
First Marketing Authorization date:
12/02/2025
Grant date:
Activation date:
Publication date:
18/06/2025
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
20/07/2037
SPC Extension Expiration:
20/07/2037
Rejection date:
Withdrawal date:

Owner

From:
18/06/2025
 
 

Name:
CSL Behring GmbH
Address:
Emil-von-Behring-Strasse 76, 35041 Marburg, Germany (DE)

Name:
CSL Limited
Address:
655 Elizabeth Street, Melbourne VIC 3000, Australia (AU)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
18/06/2025
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

Bulletin Heading:
SPC1
Bulletin edition number:
2025/08
Publication date:
03/07/2025
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
02/08/2032
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
18/06/2025 Publication 1
18/06/2025 Outgoing Correspondence 2
18/06/2025 General Document 3
18/06/2025 General Document 13
18/06/2025 General Document 71
18/06/2025 General Document 1
18/06/2025 Application Form 5
18/06/2025 Outgoing Correspondence 1